Results 191 to 200 of about 22,830 (226)
Pathology, 2022 A small subset of lung adenocarcinomas harbour ROS1 gene arrangements and are amenable to tyrosine kinase inhibitor therapy. Current practice in Australia involves screening for ROS1 rearrangements in adenocarcinomas using ROS1 immunohistochemistry (IHC) followed by confirmatory molecular testing such as fluorescence in situ hybridisation (FISH), if ...
Timothy Fielder +10 more
openaire +4 more sources
Journal of Thoracic Oncology, 2019 Plan Estatal de I+D+I 2013-2016 y 2018-2021 iLUNG ProgramIntroduction The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for ...
Noemi Reguart, Federico Rojo
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
ROS1 Targeted Therapies: Current Status
Current Oncology Reports, 2021Molecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC.Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib.
Christine M, Azelby +2 more
openaire +2 more sources
Journal of clinical pathology, 2017
ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours.
Prodipto, Pal, Zanobia, Khan
openaire +1 more source
ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours.
Prodipto, Pal, Zanobia, Khan
openaire +1 more source
ROS1: Rearrangements und Analytik
Die Pathologie, 2022Udo, Siebolts, Sabine, Merkelbach-Bruse
openaire +2 more sources
ROS1 Fusions in Cancer: A Review
Future Oncology, 2016The ROS1 gene belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. A literature review identified a ROS1 fusion in 2.54% of the patients with lung adenocarcinoma and even higher frequencies in spitzoid neoplasms and inflammatory myofibroblastic tumors.
Arnaud, Uguen, Marc, De Braekeleer
openaire +2 more sources
2015
The proto-oncogene receptor tyrosine kinase ROS1 is an evolutionarily conserved receptor that functions in development and cancer. Using genetic models and biochemical approaches, ROS1 was shown to play distinctive roles in epithelial cell differentiation during the development of a variety of organs.
openaire +1 more source
The proto-oncogene receptor tyrosine kinase ROS1 is an evolutionarily conserved receptor that functions in development and cancer. Using genetic models and biochemical approaches, ROS1 was shown to play distinctive roles in epithelial cell differentiation during the development of a variety of organs.
openaire +1 more source
2020
This tutorial chapter takes a look at changes and features introduced in ROS2, from the ROS1 user perspective. For this chapter, the Melodic and Dashing ROS distributions are used, as the latest Long-Term-Support (LTS) releases for ROS1 and ROS1 respectively.
openaire +1 more source
This tutorial chapter takes a look at changes and features introduced in ROS2, from the ROS1 user perspective. For this chapter, the Melodic and Dashing ROS distributions are used, as the latest Long-Term-Support (LTS) releases for ROS1 and ROS1 respectively.
openaire +1 more source
Cancer Research
Abstract The ROS1 gene is altered in approximately 2% of non-small cell lung cancer (NSCLC) patients. ROS1 fusions demonstrate ligand independent activity driving cell growth and survival. While several inhibitors for ROS1 have been FDA approved, including crizotinib, entrectinib and, more recently, repotrectinib, each present unique ...
Hitisha K. Patel +7 more
openaire +1 more source
Abstract The ROS1 gene is altered in approximately 2% of non-small cell lung cancer (NSCLC) patients. ROS1 fusions demonstrate ligand independent activity driving cell growth and survival. While several inhibitors for ROS1 have been FDA approved, including crizotinib, entrectinib and, more recently, repotrectinib, each present unique ...
Hitisha K. Patel +7 more
openaire +1 more source